Latest ArticlesProteomics technology, a widely utilized high-throughput method for protein analysis, aims to comprehensively analyze protein expression levels, structures, functions, modification states, and interactions. Proteolysis targeting chimeras (PROTACs), a novel drug development strategy, harnesses the natural ubiquitin-proteasome system to reduce target protein levels. This paper summarizes the advancements in proteomics technology applied to targeted protein degradation research, encompassing the identification of target proteins for PROTACs, design, screening and optimization of ligands, identification of target binding, efficiency assessment of post knockdown, and validation of pathways.
This review provides a systematic overview of the composition of styrene-isoprene-styrene triblock copolymer (SIS) hot-melt pressure-sensitive adhesives, including SIS thermoplastic elastomers, tackifiers, plasticizers, antioxidants, and fillers. Based on this, it details the preparation process and analyzes how coating and drying processes affect performance of hot-melt pressure-sensitive adhesives. Finally, this review summarizes current applications of SIS hot-melt pressure-sensitive adhesives as matrix materials to transdermal patches.
Antibody drug conjugates (ADCs) are biotherapeutic agents composed of a monoclonal antibody covalently linked to a cytotoxic payload via a chemical linker. Their unique structure combines the dual advantages of antibody-mediated targeted delivery and the potent cytotoxicity, demonstrating remarkable clinical efficacy in solid tumors, hematological malignancies and other therapeutic areas. ADCs are expected to play a pivotal role in future global drug development. Throughout the entire lifecycle of ADC development, manufacturing, and quality control, their binding affinity and biological activity critically influence therapeutic efficacy and safety. Comprehensive characterization of in vitro biological activity not only serves as the cornerstone for ensuring the clinical performance but also drives the resolution of current technical challenges and the advancement of innovative drug development. This review systematically discusses the current in vitro biological activity evaluation methods of ADCs, focusing on five functional modules based on the mechanism of ADCs: target binding activity, internalization efficiency, payload cytotoxicity, bystander effect, and Fc-mediated functions, aiming to provide methodological references for ADC development and quality control.
Based on histone deacetylase 6 (HDAC6) inhibitor SW-100 and HDAC inhibitor (compound 1)containing a benzothiadiazole dioxygen fragment as lead compounds, a series of HDAC6 inhibitor (Ⅰa - Ⅰb and Ⅱa -Ⅱh) with benzothiadiazole dioxygen fragment were designed and synthesized by pharmacophore fusion strategy. Structures of the target compounds were confirmed by MS, 1H NMR and 13C NMR. The enzyme inhibition activities of target compounds showed that the compound Ⅰe exhibited superior inhibitory activity and selectivity towards HDAC6 (Ⅰe:HDAC6 IC50=1.4 nmol/L, HDAC1/6=10.0; SW-100: HDAC6 IC50=9.4 nmol/L, HDAC1/6=14.7). The molecular docking results showed that compound Ⅰe can bind to HDAC6 protein well and interact with multiple amino acid residues. In the preliminary investigation of metabolic stability and safety, compound Ⅰe showed minimal species differences and good metabolic stability in rat and mouse liver microsomes[t1/2 (rat)=59.7 min, t1/2 (mouse)=59.2 min]. Additionally, compound Ⅰe showed low hERG inhibitory activity and weak antiproliferative effects on human neuroblastoma cells (SH-SY5Y cells), suggesting a low cardiotoxicity and good safety.
An optimized synthetic process of bentysrepinine (1) was developed. Using methyl L-tyrosinate hydrochloride (2) as the starting material, the intermediate methyl N-benzoyl-L-tyrosinate (4) was synthesized by condensation with benzoyl chloride. Hydrolysis of 4 under alkaline conditions afforded N-benzoyl-L-tyrosine (6), which was reacted with L-phenylalaninol in the present of isobutyl chloroformate (IBCF) and N-methylmorpholine (NMM) to obtain N-[N-benzoyl-L-tyrosyl]-L-phenylalaninol (7), then the reaction of 7 with 2-chloro-N, N-dimethylethylamine hydrochloride provided the target 1 with an overall yield of 55.0% (based on 2) with HPLC purity of 99.0%. The improved process is stable and easy to operate, and produces less waste water, which is suitable for industrial production.
This study optimized the synthesis process of the antigout drug benzbromarone (1). Starting from 2-ethylbenzofuran (2) and 4-methoxybenzoyl chloride (3), 2-ethyl-3- (4-hydroxybenzoyl)benzofuran sodium (16) was prepared by Friedel-Crafts acylation, demethylation, and phenolate formation in the presence of FeCl3/AlCl3 catalyst supported on activated carbon. The aqueous solution of 16 was selectively brominated under the catalysis of phosphotungstic acid to obtain the target product 1 , with the total yield of 66.0% (based on 2) and the purity of 99.91%. The improved product has high purity, low cost, and is suitable for industrial production.
2-[[1-[ (4-Bromo-1-naphthyl)methyl]imidazo[5, 4-b]pyridin-2-yl]sulfanyl]-2-methylpropanoate methyl ester, an imidazopyridine derivative, is an antigout drug candidate targeting urate transporter (URAT1 receptor) with uric acid-lowering effects. This candidate drug exhibits polymorphism. Four crystalline forms with industrial potential were yielded by adjusting solvents and temperatures during the crystallization process in this study. Identification methods for each crystalline form were established through characterization using powder X-ray diffraction, thermogravimetric analysis, and differential scanning calorimetry (DSC). Furthermore, accelerated stability studies confirmed that all four crystalline forms remained stable under 40 ℃ and relative humidity of 75% conditions. Photostability tests showed that crystalline formsⅠandⅢ were insensitive to light, while crystalline formsⅡ andⅣ exhibited significant crystalline form transformation.Solubility tests demonstrated that crystalline formⅢ had significantly better solubility than the other crystalline forms in aqueous media (25 ℃ pure water and hydrochloric acid of pH 1.2). Comprehensive analysis suggested that crystalline formⅢ has the potential for development as a superior drug polymorph.
To establish an in vitro thyroid module for thyroid pharmacodynamic research, this study constructed thyroid organoids derived from adult mouse stem cells and analyzed the stem-like cell populations of the organoid. First, the culture medium was optimized based on cell population and characteristics of the organoid as indicators. Hematoxylin and eosin (H&E) staining was used to display the histocellular structure of organoids; while immunohistochemistry (IHC)and immunofluorescence (IF) staining were employed to identify the expression of thyroid specific proteins. Meanwhile, the electrochemiluminescence assay was used to assess the secretory functions of T3 and T4. Subsequently, the stem cell gene markers in organoids were profiled by single cell RNA sequencing (scRNA-Seq), the expression of stem cell protein markers were verified by IF staining, and the cell proportion of stem cell expression was quantified by flow cytometry. The results showed that thyroid organoids derived from mouse adult stem cell were successfully established by optimizing the culture medium. Mature organoids contained thyroid follicles, and expressed characteristic molecular markers and secreted thyroid hormones. The results of scRNA-Seq revealed an enriched subpopulation of p63+Isl1+Sox2+ cells with stem cell properties. The results of IHC and flow cytometry analyses further confirmed the presence of the above stem-like cell populations in organoids and their markers expression. In conclusion, the established thyroid organoids serve as a reliable in vitro model for exploring thyroid development and pathogenesis.